Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Corona Remedies Ltd
Quarter-by-quarter operating performance
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 314 | 298 | 294 | 347 | 361 | 342 | 353 |
| Expenses + | 247 | 228 | 239 | 277 | 283 | 259 | 291 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% |
| Other Income + | 2 | 1 | 1 | 2 | 2 | -17 | 4 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 |
| Profit before tax | 57 | 58 | 43 | 61 | 70 | 55 | 54 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% |
| Net Profit + | 43 | 45 | 31 | 46 | 52 | 41 | 45 |
| EPS in Rs | 7.03 | 7.32 | 5.12 | 7.59 | 8.53 | 6.74 | 7.37 |
Financials of Corona Remedies Ltd
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | 1,403 |
| Expenses + | 444 | 509 | 471 | 600 | 756 | 859 | 956 | 1,110 |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 | 293 |
| OPM % | 13% | 15% | 18% | 3% | 14% | 15% | 20% | 21% |
| Other Income + | 3 | 3 | 5 | 7 | 7 | 5 | 5 | -8 |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 | 7 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 | 38 |
| Profit before tax | 54 | 77 | 92 | -1 | 111 | 118 | 198 | 240 |
| Tax % | 35% | 24% | 24% | -49% | 23% | 24% | 25% | 23% |
| Net Profit + | 35 | 59 | 70 | -0 | 85 | 90 | 149 | 185 |
| EPS in Rs | 74.85 | 126.70 | 150.72 | -0.08 | 13.85 | 14.80 | 24.37 | 30.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 25% | 30% | 0% |
Financials of Corona Remedies Ltd
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 | 61 |
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 | 685 |
| Borrowings + | 13 | 47 | 50 | 34 | 28 | 159 | 86 | 165 |
| Other Liabilities + | 71 | 94 | 144 | 157 | 159 | 191 | 237 | 293 |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
| Fixed Assets + | 80 | 81 | 164 | 162 | 185 | 384 | 370 | 554 |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 | 143 |
| Investments | 9 | 7 | 37 | 14 | 31 | 25 | 25 | 25 |
| Other Assets + | 200 | 278 | 330 | 321 | 314 | 301 | 348 | 482 |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
Financials of Corona Remedies Ltd
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 43 | 79 | 98 | 103 | 157 | 190 | 229 |
| Cash from Investing Activity + | -23 | -50 | -102 | -66 | -50 | -267 | -84 | -256 |
| Cash from Financing Activity + | 4 | 30 | 0 | -30 | -45 | 99 | -107 | 25 |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 | -1 |
| Free Cash Flow | 19 | 1 | 6 | 64 | 9 | -129 | 99 | 55 |
| CFO/OP | 49% | 65% | 101% | 557% | 100% | 112% | 97% | 95% |
Financials of Corona Remedies Ltd
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 105 | 131 | 44 | 36 | 36 | 36 | 38 |
| Inventory Days | 69 | 52 | 77 | 184 | 182 | 158 | 200 | 175 |
| Days Payable | 126 | 110 | 182 | 211 | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 38 | 48 | 27 | 17 | 55 | 10 | 14 | 7 |
| Working Capital Days | 67 | 81 | 86 | 16 | 30 | -2 | 9 | -15 |
| ROCE % | 30% | 27% | 1% | 29% | 25% | 31% | 33% |